# Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple‐negative breast cancer patients

**Authors:** Chiara Massa, Thomas Karn, Karsten Weber, Andreas Schneeweiss, Claus Hanusch, Jens Uwe Blohmer, Dirk‐Michael Zahm, Christian Jackisch, Marion van Mackelenbergh, Jörg Thomalla, Frederik Marmé, Jens Huober, Volkmar Müller, Christian Schem, Anja Müller, Elmar Stickeler, Katharina Biehl, Peter A. Fasching, Michael Untch, Sibylle Loibl, Carsten Denkert, Barbara Seliger

PMC · DOI: 10.1002/ctm2.1617 · Clinical and Translational Medicine · 2024-04-25

## Full-text entities

- **Genes:** CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}
- **Diseases:** breast cancer (MESH:D001943)
- **Chemicals:** durvalumab (MESH:C000613593)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11045558/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11045558/full.md

## References

9 references — full list in the complete paper: https://tomesphere.com/paper/PMC11045558/full.md

---
Source: https://tomesphere.com/paper/PMC11045558